Daniel Lochner
Known title: Chief Financial OfficerCIK: 0001791187
Daniel Lochner's purchase track record
Daniel Lochner has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 2/10/2026 | TECX | $130K | +32.8% | +51.4% | +11.3% |
| 2/5/2025 | TECX | $250K | -59.5% | -50.5% | +4.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| TECX | ▼ Sell | Tax Withholding | 520 | $12K | 9/25/2026 | View on chart |
| TECX | ▲ Buy | Grant | 26,500 | $0 | 3/4/2026 | View on chart |
| TECX | ▲ Buy | Open Market | 6,000 | $130K | 2/10/2026 | View on chart |
| TECX | ▼ Sell | Tax Withholding | 2,077 | $48K | 2/4/2026 | View on chart |
| TECX | ▲ Buy | Grant | 5,430 | $0 | 9/25/2025 | View on chart |
| TECX | ▲ Buy | Open Market | 4,617 | $250K | 2/5/2025 | View on chart |
| TECX | ▲ Buy | Grant | 18,074 | $0 | 2/4/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
TECX Reports Positive Phase 1 Data for TX2100 in HHT
Tectonic Therapeutic released results from its Phase 1 study of TX2100, a treatment aimed at hereditary hemorrhagic telangiectasia. The data showed the drug was safe, well tolerated and demonstrated expected pharmacokinetic behavior. These early findings support continued development of the candidate. The news arrives while the stock is trading near a long‑term support level.
TECX Reports Positive Phase 1 Data for TX2100 in HHT. Tectonic Therapeutic released results from its Phase 1 study of TX2100, a treatment aimed at hereditary hemorrhagic telangiectasia. The data showed the drug was safe, well tolerated and demonstrated expected pharmacokinetic behavior. These early findings support continued development of the candidate. The news arrives while the stock is trading near a long‑term support level.